To test if the downregulation of MyD88 by ASO leads to the suppression of tumor growth in established tumors and if the activity of MyD88 ASO can be further improved with GalNAc conjugation in this model, 6-month-old HCC-bearing animals were treated with either an unconjugated (at 25 mg/kg = 4.5 μmole) or a GalNAc-conjugated (at 7.5 mg/kg = 1.02 μmole) MyD88 ASO along with a negative control ASO (at 25 mg/kg) (n = 16/group) subcutaneously twice a week for 3 months. The gene discussed is MYD88; the disease is hepatocellular carcinoma.